Study Examining PrEP-001 in Subjects With Asthma

Summary

Phase 2 study, to examine the prophylactic efficacy, safety and tolerability of PrEP-001 in asthmatics who have been infected with the human rhinovirus (HRV16) after receiving two doses of the study drug/placebo.

Timeline

Start

2015-12-11

Primary completion

2016-09

Completion

2016-09

Drugs

Indications